Financial Performance - The company's revenue for Q1 2024 reached ¥223,087,720.62, a significant increase from ¥124,496,642.13 in Q1 2023, representing an increase of approximately 78.9%[10] - Gross profit for the same period was ¥204,787,581.71, resulting in a gross margin of approximately 91.8%[10] - Net profit for Q1 2024 was ¥104,328,856.62, compared to ¥48,556,745.85 in Q1 2023, indicating a year-over-year growth of approximately 115.5%[10] - Basic and diluted earnings per share for Q1 2024 were both ¥1.49, up from ¥0.69 in the previous year[8] - Operating profit for Q1 2024 was ¥118,076,923.42, compared to ¥50,605,054.49 in Q1 2023, indicating an increase of about 132.9%[16] - Net profit for Q1 2024 was ¥101,368,431.82, up from ¥42,868,918.46 in Q1 2023, reflecting a growth of approximately 136.2%[16] - The company achieved a total comprehensive income of ¥104,328,856.62 for Q1 2024, compared to ¥48,556,745.85 in Q1 2023[11] - Total operating revenue for Q1 2024 reached ¥225,500,687.12, a significant increase from ¥128,061,724.54 in Q1 2023, representing a growth of approximately 76.2%[15] Assets and Liabilities - Total assets increased to ¥1,525,478,803.30 from ¥1,434,538,371.98, representing a growth of approximately 6.8% year-over-year[2] - Non-current assets totaled ¥704,137,214.90, up from ¥681,951,175.01, indicating a rise of about 3.6%[1] - Current liabilities decreased to ¥248,640,050.73 from ¥262,313,751.86, reflecting a reduction of approximately 5.2%[1] - The total liabilities decreased to ¥441,820,925.44 from ¥455,079,524.12, showing a decline of about 2.9%[6] - The total liabilities to assets ratio decreased to 30.87% from 33.56%, reflecting improved financial stability[30] - The company reported a significant increase in contract liabilities, which rose by 58.70% to ¥39,325,062.94, indicating higher prepayments from customers[31] Cash Flow and Liquidity - Cash and cash equivalents rose to ¥543,097,678.30 from ¥488,941,431.34, marking an increase of about 11.1%[3] - Cash and cash equivalents at the end of Q1 2024 were ¥572,006,323.20, compared to ¥89,114,295.37 at the end of Q1 2023, reflecting a strong liquidity position[13] - Cash flow from operating activities for Q1 2024 was ¥105,560,954.38, a substantial increase from ¥17,315,089.32 in Q1 2023[18] - Net cash flow from operating activities increased by 765.57% to ¥104,883,073.28, reflecting significant growth in sales and net profit[32] - The company reported a net cash outflow from investment activities of ¥33,216,029.09 in Q1 2024, an improvement from a net outflow of ¥89,425,358.45 in Q1 2023[18] Research and Development - Development expenditures increased to ¥50,301,794.09 from ¥25,960,499.73, representing a growth of approximately 93.8%[1] - The company’s R&D expenditures increased, with development costs rising by 93.76% to ¥50,301,794.09, driven by ongoing projects in medical devices and antiviral drug development[30] - Research and development expenses for Q1 2024 were ¥10,273,125.12, slightly down from ¥11,602,997.27 in Q1 2023[15] Shareholder Information - The number of ordinary shareholders increased to 2,703, indicating a broader shareholder base[34] - There were no significant changes in the top ten shareholders' holdings, with the largest shareholder holding 58.89%[37] - The employee stock ownership plan is currently in implementation, involving senior management and core employees participating in a public offering[41] Other Notable Information - The company has no major litigation or arbitration matters reported during the period[40] - The company has not engaged in any share buyback activities during the reporting period[40] - The company provided a guarantee for a loan to the Bank of Communications, with a guarantee balance of CNY 24,986,300 as of March 31, 2024[41]
锦波生物(832982) - 2024 Q1 - 季度财报